Prof. Mark Haden is listed as an executive officer on 1 SEC Form D filing by 1 issuer in Feb 2024: Clearmind Medicine Inc. (Vancouver, British Columbia, Canada (as filed: A1) — biotechnology — 2024; $2.4M reported sold to 12 investors).
What this means One deal on file with the SEC, filed Feb 2024. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Alan Rootenberg (1 shared filing), Amitay Weiss (1 shared filing), Asaf Itzhaik (1 shared filing), Dr. Adi Zuloff-Shani (1 shared filing), Oz Adler (1 shared filing) and 1 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Prof.. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 1 public filing for Prof. Mark Haden and found 1 difference: Form D filed 27 days after the first sale.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.